21-Jan-2025 12:45 PM CST - Business Insider Amgen 2025 guidance could miss estimates, says Wells Fargo Wells Fargo sees downside to Amgen's (AMGN) 2025 consensus estimates, saying the company' sales guidance could came in below expectations. It
17-Jan-2025 2:36 PM CST - Investing Piper Sandler maintains Amgen stock Overweight with $310 target Piper Sandler reiterated its Overweight rating on Amgen (NASDAQ:AMGN) shares, maintaining a price target of $310.00. The company, which boasts a "GOOD" overall financial health score according to InvestingPro analysis,
17-Jan-2025 10:11 AM CST - Benzinga FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation The CodeBreaK 300 results demonstrated that Lumakras 960 mg daily plus Vectibix (n=53) showed an improved median progression-free survival (PFS) of 5.6 months compared to 2 months on the investigator's choice of care (n=54).
17-Jan-2025 5:46 AM CST - Business Insider Piper Sandler Reaffirms Their Buy Rating on Amgen (AMGN) Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN - Research Report) today and set a price target of $310.00. The
15-Jan-2025 6:45 AM CST - Business Insider Truist Financial Releases a Hold Rating on Amgen (AMGN) In a report released today, Srikripa Devarakonda from Truist Financial assigned a Hold rating to Amgen (AMGN - Research Report). The company's
21-Jan-2025 12:45 PM CST - Business Insider Amgen 2025 guidance could miss estimates, says Wells Fargo Wells Fargo sees downside to Amgen's (AMGN) 2025 consensus estimates, saying the company' sales guidance could came in below expectations. It
17-Jan-2025 2:36 PM CST - Investing Piper Sandler maintains Amgen stock Overweight with $310 target Piper Sandler reiterated its Overweight rating on Amgen (NASDAQ:AMGN) shares, maintaining a price target of $310.00. The company, which boasts a "GOOD" overall financial health score according to InvestingPro analysis,
17-Jan-2025 10:11 AM CST - Benzinga FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation The CodeBreaK 300 results demonstrated that Lumakras 960 mg daily plus Vectibix (n=53) showed an improved median progression-free survival (PFS) of 5.6 months compared to 2 months on the investigator's choice of care (n=54).
17-Jan-2025 5:46 AM CST - Business Insider Piper Sandler Reaffirms Their Buy Rating on Amgen (AMGN) Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN - Research Report) today and set a price target of $310.00. The
15-Jan-2025 6:45 AM CST - Business Insider Truist Financial Releases a Hold Rating on Amgen (AMGN) In a report released today, Srikripa Devarakonda from Truist Financial assigned a Hold rating to Amgen (AMGN - Research Report). The company's
